Innoviva (INVA) Payables (2010 - 2026)
Innoviva's (INVA) quarterly Payables came in at $6.5 million in Q1 2026, up 38.68% YoY from $4.7 million in Q1 2025, and up 31.25% on a QoQ basis from $5.0 million in Q4 2025.
Analysis
Innoviva (INVA) Payables (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Payables data on file, last reported at $6.5 million in Q1 2026.
- Quarterly Payables rose 38.68% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (up 38.68% YoY) and the FY2025 annual result came in at $5.0 million, up 132.93% from the prior year.
- Payables grew to $6.5 million in Q1 2026, from $5.0 million in the prior quarter.
- In the past five years, Payables ranged from a high of $6.7 million in Q4 2023 to a low of $890000.0 in Q1 2024.
- A 5-year average of $4.2 million and a median of $4.3 million in 2022 frame the typical range for Payables.
- Annual changes were most pronounced in 2022 — Payables surged 14310.0% — and 2024, when it plunged 85.0%.
- Tracing INVA's Payables over 5 years: stood at $2.9 million in 2022, then surged by 128.55% to $6.7 million in 2023, then sank by 68.26% to $2.1 million in 2024, then soared by 132.93% to $5.0 million in 2025, then soared by 31.25% to $6.5 million in 2026.
- The last three Payables figures came in at $6.5 million (Q1 2026), $5.0 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | 4.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.02 Mn |
| Mar 31, 2026 | 6.52 Mn |
| Dec 31, 2025 | 4.97 Mn |
| Sep 30, 2025 | 6.24 Mn |
| Jun 30, 2025 | 5.38 Mn |
| Mar 31, 2025 | 4.70 Mn |
| Dec 31, 2024 | 2.13 Mn |
| Sep 30, 2024 | 4.17 Mn |
| Jun 30, 2024 | 2.04 Mn |
| Mar 31, 2024 | 890,000.00 |
| Dec 31, 2023 | 6.72 Mn |
| Sep 30, 2023 | 3.78 Mn |
| Jun 30, 2023 | 4.59 Mn |
| Mar 31, 2023 | 5.93 Mn |
| Dec 31, 2022 | 2.94 Mn |
| Sep 30, 2022 | 3.81 Mn |
| Jun 30, 2022 | 4.32 Mn |
| Mar 31, 2022 | 1.81 Mn |
| Dec 31, 2021 | 27,000.00 |
| Sep 30, 2021 | 89,000.00 |